ArticleJournal of translational medicine2026
Interpretative diagnostic model for neuroblastoma metastases using bone marrow cytology.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06703944 (Bone Marrow Cytology-based Artificial Intelligence Model for Detection and Prognosis of Neuroblastoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bone Marrow Cytology-based Artificial Intelligence Model for Detection and Prognosis of Neuroblastoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBone marrow (BM) is the most common site of metastatic disease at diagnosis and a frequent site of relapse in neuroblastoma. Digital cytology images of BM smears offer a rich data source for artificial intelligence models, which may potentially facilitate more cost-effective risk stratification within the diagnostic workflow. This study aims to develop an interpretable cytology model for detecting BM metastasis in pediatric neuroblastoma.
methodsThis retrospective diagnostic study used Wright-Giemsa–stained BM cytology images from 359 neuroblastoma patients who underwent BM screening between January 2019 and June 2024 across multiple centers in China. After the quality evaluation, we generated 1384,007 patches from BM digital cytology to develop and validate the cytology model. In the model construction, we integrated a multiple-instance learning framework with convolutional neural networks to extract cytology features, referred to as cMIL. The cytology model was trained for BM metastasis detection and risk stratification with interpretability.
resultsFor metastasis detection, the cytology model achieved an AUC of 0.924 (95% CI, 0.775–1.000) in the training cohort. Performance remained strong in external validation, with AUCs of 0.826 (95% CI, 0.741–0.911) in Cohort A and 0.795 (95% CI, 0.684–0.906) in Cohort B, indicating consistent performance across independent multicenter cohorts. The cMIL score also successfully stratified patients in terms of survival outcomes (log-rank p < 0.05). Interpretability analyses further demonstrated that the model’s predictions were associated with clinically relevant cytological features.
conclusionsIn this retrospective diagnostic study, the developed cytology model demonstrated high discriminative performance in detecting BM metastasis and captured the underlying complexity and heterogeneity of BM. These findings suggest that the cytology model could serve as a promising tool for improving metastasis detection and risk stratification in patients with neuroblastoma, potentially contributing to personalized treatment strategies and enhanced disease monitoring.
trial registrationThis retrospective study was registered with ClinicalTrials.gov (NCT06703944) on November 21, 2024. Study title: bone marrow cytology-based artificial intelligence model for detection and prognosis of neuroblastoma. ( https://register.clinicaltrials.gov ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.